These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6474162)

  • 41. Evidence for a daily rhythm of plasma HVA in normal controls but not in schizophrenic patients.
    Doran AR; Pickar D; Labarca R; Douillet P; Wolkowitz OM; Thomas JW; Roy A; Paul SM
    Psychopharmacol Bull; 1985; 21(3):694-7. PubMed ID: 4034886
    [No Abstract]   [Full Text] [Related]  

  • 42. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.
    Garver DL; Holcomb JA; Christensen JD
    J Clin Psychiatry; 2000 Dec; 61(12):964-72; quiz 973. PubMed ID: 11206608
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma homovanillic acid and other predictors of clozapine response.
    Pickar D
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():516A-517A. PubMed ID: 1498935
    [No Abstract]   [Full Text] [Related]  

  • 45. Plasma catecholamine metabolites and early response to haloperidol.
    Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
    J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics.
    Kim YK; Kim L; Lee MS
    Schizophr Res; 2000 Sep; 44(3):165-75. PubMed ID: 10962218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period.
    Sharma RP; Javaid JI; Davis JM; Janicak PG
    Biol Psychiatry; 1998 Sep; 44(6):488-92. PubMed ID: 9777181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.
    Takase M; Kimura H; Kanahara N; Nakata Y; Iyo M
    J Psychopharmacol; 2020 May; 34(5):540-547. PubMed ID: 31961236
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
    Davidson M; Losonczy MF; Mohs RC; Lesser JC; Powchik P; Freed LB; Davis BM; Mykytyn VV; Davis KL
    Neuropsychopharmacology; 1987 Dec; 1(1):17-23. PubMed ID: 3509064
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Studies of plasma homovanillic acid as an index of brain dopamine function.
    Kendler KS; Hsieh JY; Davis KL
    Psychopharmacol Bull; 1982 Oct; 18(4):152-5. PubMed ID: 7156280
    [No Abstract]   [Full Text] [Related]  

  • 51. CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment.
    Frecska E; Perényi A; Bagdy G; Révai K
    Psychiatry Res; 1985 Nov; 16(3):221-6. PubMed ID: 2868474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.
    Volavka J; Douyon R; Convit A; Czobor P; Cooper TB
    Arch Gen Psychiatry; 1992 Dec; 49(12):999-1000. PubMed ID: 1449388
    [No Abstract]   [Full Text] [Related]  

  • 53. Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA.
    Doran AR; Rubinow DR; Wolkowitz OM; Roy A; Breier A; Pickar D
    Biol Psychiatry; 1989 Feb; 25(4):431-9. PubMed ID: 2564787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
    Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
    Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated plasma homovanillic acid in depressed females with melancholia and psychosis.
    Devanand DP; Bowers MB; Hoffman FJ; Nelson JC
    Psychiatry Res; 1985 May; 15(1):1-4. PubMed ID: 3859880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
    Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
    Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
    Koreen AR; Lieberman J; Alvir J; Mayerhoff D; Loebel A; Chakos M; Amin F; Cooper T
    Arch Gen Psychiatry; 1994 Feb; 51(2):132-8. PubMed ID: 7905259
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
    Davidson M; Kendler KS; Davis BM; Horvath TB; Mohs RC; Davis KL
    Psychiatry Res; 1985 Oct; 16(2):95-9. PubMed ID: 3865258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cholecystokinin, dopamine and schizophrenia.
    Garver DL; Beinfeld MC; Yao JK
    Psychopharmacol Bull; 1990; 26(3):377-80. PubMed ID: 2274639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients.
    Zumárraga M; Dávila R; González-Torres MA; Anguiano JB; Zabalo MJ; Basterreche N; Arrúe A; Zamalloa MI; Guimón J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):713-9. PubMed ID: 17291661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.